Download PDF
Thromb Haemost 1987; 58(03): 822-826
DOI: 10.1055/s-0038-1645997
Original Article
Schattauer GmbH Stuttgart

Tissue Plasminogen Activator and Urokinase in Normal, Dysplastic and Cancerous Squamous Epithelium of the Uterine Cervix

G Larsson
*   The Department of Obstetrics and Gynaecology, University Lund, Sweden
,
Å Larsson
**   The Department of Oral Pathology, University Lund, Sweden
,
B Åstedt
*   The Department of Obstetrics and Gynaecology, University Lund, Sweden
› Author Affiliations
Further Information

Publication History

Received 11 August 1986

Accepted after revision 12 May 1987

Publication Date:
28 June 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The distribution of tissue plasminogen activator (t-PA) and urokinase (u-PA) was investigated immunohistochemically in squamous epithelium of the uterine cervix, in normal and dysplastic conditions as well as in preinvasive and invasive carcinomas. Normal epithelium showed presence of both t PA and u-PA immunoreactivity only in the superficial cellular layer, whereas in preinvasive lesions they were present in all layers. In sections of normal specimens as well as preinvasive lesions the UK immunoreactivity was weaker compared to that of t-PA. Tnvnsivc lesions showed a patchy distribution of t-PA and u-PA immunoreactivity. Furthermore, it could be demonstrated that stromal cells close to the infiltrating malignant squamous epithelium contained t-PA immunoreactivity and also u-PA immunoreactivity. Further immunohistochemical studies disclosed that these cells were macrophages.

Keywords

Plasminogen activator - Urokinase - Dysplasia - Fibrinolysis - Cervical carcinoma
 

  • References

  • 1 Danø K, Andreasen PA, Grpndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 1985; 44: 139-266
    PubMedGoogle Scholar
  • 2 Holmberg L, Kristoffersson A-C, Lecander I, Wallén P, Åstedt B. Immunoradiometric quantification of tissue plasminogen activator secreted by fetal organs. Comparison with urokinase. Scand J Clin Lab Invest 1982; 42: 347-354
    CrossrefPubMedGoogle Scholar
  • 3 Astedt B, Pandolfi M. On release and synthesis of fibrinolytic activators in human organ culture. Eur J Clin Biol Res 1972; 17: 261-267
    PubMedGoogle Scholar
  • 4 Wun T-C, Ossowski L, Reich E. A proenzyme form of human urokinase. J Biol Chem 1982; 257: 7262-7268
    PubMedGoogle Scholar
  • 5 Husain SS, Gurewich V, Lipinski B. Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine. Arch Biochem Biophys 1983; 220: 31-38
    CrossrefPubMedGoogle Scholar
  • 6 Tissot J-D, Schneider Ph, Hauert J, Ruegg M, Kruithof E KO, Bachmann F. Isolation from human plasma of a plasminogen activator identical to urinary high molecular weight urokinase. J Clin Invest 1982; 70: 1320-1323
    CrossrefPubMedGoogle Scholar
  • 7 Wun T-C, Schleuning W-D, Reich E. Isolation and characterization of urokinase from human plasma. J Biol Chem 1982; 257: 3276-3283
    PubMedGoogle Scholar
  • 8 Astedt B, Glifberg I, Mattsson W, Trope C. Arrest of growth of ovarian tumor by tranexamic acid. JAMA 1977; 238: 154-155
    CrossrefPubMedGoogle Scholar
  • 9 Astedt B. Adjuvant treatment of ovarian carcinoma with tranexamic acid. J Clin Pathol 1980; 33: 74-76
    CrossrefPubMedGoogle Scholar
  • 10 Astedt B, Henriksson P, Nilsson I-M, Svanberg L. Regression of hemangioma - thrombocytopenia syndrome. Acta Obstet Gynecol Scand 1982; 62: 479-480
    PubMedGoogle Scholar
  • 11 Astedt B, Holmberg L. Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature 1976; 261: 595-597
    CrossrefPubMedGoogle Scholar
  • 12 Rifkin D, Loeb J, Moore G, Reich E. Properties of plasminogen activators formed by neoplastic human cell cultures. J Exp Med 1974; 139: 1317-1328
    CrossrefPubMedGoogle Scholar
  • 13 Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-7041
    PubMedGoogle Scholar
  • 14 Mesa-Tejada R, Pascal RR, Fenoglio CM. Immunoperoxidase: A sensitive immunohistochemical technique as a “special Stain” in the diagnostic pathology laboratory. Human Pathol 1977; 8: 313-320
    CrossrefPubMedGoogle Scholar
  • 15 Wallen P, Ranby M, Bergsdorf N, Kok P. Purification and characterization of tissue plasminogen activator: on the occurrence of two different forms and their enzymatic properties. In: Progress in Fibrinolysis. Davidson JF, Nilsson I-M, Astedt B. (eds.) Churchill Livingstone; Edinburgh: 1981. 05 16-23
    Google Scholar
  • 16 Astedt B, Fagher U. Immunoradiometrische Bestimmung des Blut/ Gewebe-Plasminogenaktivators bei der Thrombophilie. Folia Haematol 1984; 4: 475-479
    PubMedGoogle Scholar
  • 17 Holmberg L, Bladh B, Astedt B. Purification of urokinase by affinity chromatography. Biochim Biophys Acta 1976; 445: 215-222
    CrossrefPubMedGoogle Scholar
  • 18 Holmberg L, Lecander I, Persson B, Astedt B. An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture. Biochim Biophys Acta 1978; 544: 128-137
    CrossrefPubMedGoogle Scholar
  • 19 Astedt B. No crossreaction between circulating plasminogen activator and urokinase. Thromb Res 1979; 14: 535-539
    CrossrefPubMedGoogle Scholar
  • 20 Sternberger LA, Hardy Jr PH, Cuculis JJ, Meyer HG. The unlabeled antibody enzyme method of immunohistochemistry. Preparation and properties of soluble antigen-antibody complex (horseradish peroxidase-antihorseradish peroxidase) and its use in identification of spirochetes. J Histochem Cytochem 1970; 18: 315-333
    CrossrefPubMedGoogle Scholar
  • 21 Larsson A, Astedt B. Immunohistochemical localisation of tissue plasminogen activator and urokinase in the vessel wall. J Clin Pathol 1985; 38: 140-145
    CrossrefPubMedGoogle Scholar
  • 22 Isaacson P, Wright DH. Anomalous staining patterns in immunohistologic studies of malignant lymphoma. J Histochem Cvtochem 1979; 27: 1197-1199
    PubMedGoogle Scholar
  • 23 Burgdorf W HC, Mukai K, Rosai J. Immunohistochemical identification of factor VIII related antigen in endothelial cells of cutaneous lesions of alleged vascular nature. Am J Clin Pathol 1981; 75: 167-171
    CrossrefPubMedGoogle Scholar
  • 24 Schested M, Hou-Jensen K. Factor VIII related antigen as an endothelial cell marker in benign and malignant diseases. Virchows Arch (Pathol Anat) 1981; 391: 217-225
    CrossrefPubMedGoogle Scholar
  • 25 Electricwala A, Atkinson T. Purification and properties of plasminogen activators from epithelial cells. Eur J Biochem 1985; 147: 511-516
    PubMedGoogle Scholar
  • 26 Waller EK, Schleuning W-D. Induction of fibrinolytic activity in HeLa cells by phorbol mvristate acetate. J Biol Chem 1985; 260: 6354-6360
    PubMedGoogle Scholar
  • 27 Isseroff RR, Fusenig NE, Rifkin DB. Plasminogen activator in differentiating mouse keratinocytes. J Invest Dermatol 1983; 80: 217-222
    CrossrefPubMedGoogle Scholar
  • 28 Jensen RH, Bigbee WL, Zimmerman AL, King EB. Plasminogen activator as a diagnostic marker for preneoplastic cells in human gynecologic specimens. Acta Cytol 1979; 23: 105-113
    PubMedGoogle Scholar
  • 29 Birkedal-Hansen H, Taylor RE. Production of three plasminogen activators and an inhibitor in keratinocyte cultures. Biochim Biophys Acta 1983; 756: 308-318
    CrossrefPubMedGoogle Scholar
  • 30 Weiss G, Beller FK. Tissue activator of the fibrinolytic enzyme in the female reproductive system. Obstet Gynecol 1969; 34: 809-819
    PubMedGoogle Scholar
  • 31 Weiss G, Beller FK. Localisation of fibrinolytic activity in uterine cancer. Am J Obstet Gynecol 1969; 103: 1023-1027
    CrossrefPubMedGoogle Scholar
  • 32 Ljungn’r H, Holmberg L, Kjeldgaard A, Nilsson I-M, Åstedt B. Immunological characterization of plasminogen activators in a human vessel wall. J Clin Pathol 1983; 36: 1046-1049
    CrossrefPubMedGoogle Scholar
  • 33 Isseroff RR, Rifkin DB. Plasminogen is present in the basal layer of the epidermis (abstr). J Invest Dermatol 1982; 78: 359
    PubMedGoogle Scholar
  • 34 Morioka S, Jensen PJ, Lazarus GS. Human epidermal plasminogen activator. Exp Cell Res 1985; 161: 364
    CrossrefPubMedGoogle Scholar
  • 35 Gröndahl-Hansen J, Nielsen LS, Kristensen P, Gröndahl-Hansen V, Andrcascn PA, Danö K. Plasminogen activator in psoriatic scales is of the tissue type PA as identified by monoclonal antibodies. Br J Dermatol 1985; 113: 257
    CrossrefPubMedGoogle Scholar
  • 36 Salo T, Liotta LA, Keski-Oja J, Tuipeeniemi-Hujanen T, Tryggvason K. Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells-role in metastasis. Int J Cancer 1982; 30: 669-673
    CrossrefPubMedGoogle Scholar
  • 37 Quigley JP, Martin BM, Goldfarb RH, Scheiner CJ, Muller WD. Involvement of serine proteases in growth control and malignant transformation. In: Hormones and Cell Cultures. Cold Spring Harbor Conferences on Cell Proliferation 1979; 6: 219-238
    PubMedGoogle Scholar
  • 38 Polverini PJ, Leibovich SJ. Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab Invest 1984; 51: 635-642
    PubMedGoogle Scholar
  • 39 Vassalli J-D, Dayer J-M, Wohlwend A, Belin D. Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. J Exp Med 1984; 159: 1653-1668
    CrossrefPubMedGoogle Scholar
  • 40 Saksela O, Tapani H, Vaheri A. Urokinase-type plasminogen activator and its inhibitor secreted by cultured human, monocyte-macrophages. J Cell Physiol 1985; 122: 125-132
    CrossrefPubMedGoogle Scholar
  • 41 Schreiber AD, Kelley M, Dziarski A, Levinson AI. Human monocyte functional heterogeneity: monocyte fractionation by discontinuous albumin gradient centrifugation. Immunology 1983; 49: 231-238
    PubMedGoogle Scholar